This study is a prospective, single arm, multi-center, interventional, pre-market trial to obtain clinical data from Chinese implanting centers to support product registration of the Medtronic CoreValve™ Evolut™ PRO System (TAV, DCS and LS) with the National Medical Product Administration (NMPA) in China. Estimating 65 subjects with a maximum of up to 70 subjects in China with an attempted implant and followed the assessment with pre and post-procedure, discharge, 30 days(primary endpoint), 6months, 1 year, and annually through 5 years.
Interventional study to evaluate the safety and efficacy of the Medtronic CoreValve™ Evolut™ PRO System when used by China implanting centers in Chinese patients with severe symptomatic aortic stenosis (AS) who are at high risk for Surgical Aortic Valve Replacement (SAVR).